| Bioactivity | SY-LB-57 is a highly potent bone morphogenetic protein (BMP) receptor signaling agonist. SY-LB-57 can be used in studies of diseases such as fractures and pulmonary arterial hypertension[1]. | ||||||||||||
| Invitro | SY-LB-57 (0.01-1000 μM, 24 h) can significantly induce cell proliferation at concentrations below 10 µM with an IC50 value of 807.93 µM in C2C12 cells[1].SY-LB-57 (0.01-10 μM, 15-30 min) increases the phosphorylation of Smad protein and promotes p-Smad nuclear translocation while activates the PI3K/Akt pathway and induces cytoplasmic localization of p-Akt[1].SY-LB-57 (0.01-10 μM, 24 h) can induce cell cycle shift towards proliferation[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | SY-LB-57 | ||||||||||||
| CAS | 2253719-35-4 | ||||||||||||
| Formula | C16H13N3O | ||||||||||||
| Molar Mass | 263.29 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sheyda Najafi, et al. Discovery of a novel class of benzimidazoles as highly effective agonists of bone morphogenetic protein (BMP) receptor signaling. Sci Rep. 2022 Jul 15;12(1):12146. |